BIOA compared with DRUG: revenue, margins and what each company keeps, and the suppliers and customers both name

BIOABioAge Labs, Inc.

Mkt capRevenueRevenue

DRUGBright Minds Biosciences Inc.

Mkt capRevenueRevenue

Compare

BIOABioAge Labs, Inc.

DRUGBright Minds Biosciences Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only BIOA 0

None

Shared 0

No disclosed counterparties: BIOA.

Only DRUG 11

—Gerep Realtyunlistedsupplier

—Technology Innovation Centerunlistedsupplier

—ZoE Life Fulton Labs Incubatorunlistedsupplier

—Dr. Cunningham labunlistedsupplier

7 more · DRUG chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

BIOABioAge Labs, Inc.

5.60▼−3.45%

Mkt cap$260.1MRevenue$2MQ2 FY26Revenue$9MFY25

DRUGBright Minds Biosciences Inc.

25.10▼−4.20%

Regular sessionNov 3 '26

Mkt cap$200.1MRevenue—Revenue—

Compare

Regular sessionNov 3 '26

BIOABioAge Labs, Inc.

DRUGBright Minds Biosciences Inc.

5.60▼−3.45%

Price

25.10▼−4.20%

$260.1M

Mkt cap

$200.1M

Q2 FY26$2M

Revenue

—

FY25$9M

Revenue

—

BIOA5.60▼−3.45%vsDRUG25.10▼−4.20%Regular sessionNov 3 '26